Brazikumab (INN; development code MEDI2070) is a human monoclonal antibody designed for the treatment of Crohn's disease.[1][2] that targets IL-23.[3]

This drug was developed by MedImmune.

References

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Brazikumab, American Medical Association
  2. ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
  3. ^ Hanžel J, D'Haens GR (April 2020). "Anti-interleukin-23 agents for the treatment of ulcerative colitis". Expert Opinion on Biological Therapy. 20 (4): 399–406. doi:10.1080/14712598.2020.1697227. PMID 31760827.
Allikas: https://en.wikipedia.org/wiki/Brazikumab
No tags for this post.